ExpreS2ion Biotechnologies, Cancer Research U.K. enter license agreement
ExpreS2ion Biotechnologies has signed a research license agreement to provide the Protein Purification Facility at Cancer Research U.K.’s London Research Institute with access to its Drosophila Schneider-2 cell-based technology platform—ExpreS2—for protein production.
The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Protein Purification Facility. The platform will be used to address expression of complex and “challenging” proteins, including Fab fragments and other proteins.
This license is a relevant addition to ExpreS2ion Biotechnologies’ vision of making its production platform available to academic centers of excellence globally, and making S2 one of the standard protein production platforms in the immunotherapy and therapeutic protein segments.
“We have in the past used the ExpreS2 protein expression system to enable the advance of cancer projects, and this Research License confirms the relevance of the system in complementing existing protein needs in cancer research,” said Dr. Charlotte Dyring, chief executive officer of ExpreS2ion Biotechnologies.
“The technology complements our baculovirus-based protein expression activities perfectly and we look forward to expanding the application range of the technology to other projects involving other promising protein targets implicated in cancer,” said Dr. Svend Kjaer, head of the Protein Purification Facility.